Evidence map›Paper›PMID 42857836›Full record

ArticleJournal of cellular signaling2026

CD28 is Not Required for T cell Activation.

Gongyi Zhang

Abstract read
In one paragraph

Article in Journal of cellular signaling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Gongyi ZhangDepartment of Immunology and Genomic Medicine, National Jewish Health, Denver, USA.

Funding

Histone Arginine Demethylation through CleavageR01GM135421 · NIGMS · NATIONAL JEWISH HEALTH · PI ZHANG, GONGYI · 2020 to 2023
$1.7M
NIGMS NIH HHS R01 GM135421
6 · The paper itself

Abstract

It has been almost four decades since CD28 was identified as a major player (co-stimulator) of T cell activation and has been recognized as one of the major milestones in the T cell field. However, the exact underlying mechanism involved in the activation of CD28 still remains poorly understood. Most importantly, the depletion of CD28 in mice did not lead to a major defect in T cell activation response, even when combined with the deletion of ICOS, a homolog of CD28. Here, we propose that CD28 is just a survival receptor, which works together with CD45 to maintain T cell survival. It does not participate in the activation of the T-cell activation process by antigen-presenting cells (APCs)

Indexed as

Anti-CD28Anti-CD3CD28CD3CD45GalectinLCKPI3K

Identifiers

PMID42857836
PMCPMC13652506

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.